摘要
【目的】探讨参松养心胶囊联合黛力新治疗冠心病经皮冠状动脉介入治疗(PCI)术后抑郁患者的临床疗效。【方法】选择2022年6月至2024年12月本院收治的102例冠心病PCI术后抑郁患者,根据随机数字表法分为观察组(采用黛力新+参松养心胶囊治疗)和对照组(采用黛力新治疗),每组51例。治疗3个月后,比较两组中医证候评分、抑郁情况及临床疗效,比较两组神经递质因子[脑源性神经营养因子(BDNF)、5-羟色胺(5-HT)]、心功能指标[左心室舒张末内径(LVEDD)、左室射血分数(LVEF)]及不良反应发生情况。【结果】治疗1个月、治疗3个月,两组患者中医证候主证、次证评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组汉密尔顿抑郁量表(HAMD)评分均低于治疗前,且观察组均低于对照组,差异有统计学意义(P<0.05)。观察组临床总有效率为94.12%(48/51),高于对照组的80.39%(41/51),差异有统计学意义(P<0.05)。治疗1个月、治疗3个月,两组患者血清BDNF、5-HT水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗1个月、治疗3个月,两组LVEF均高于治疗前,LVEDD均低于治疗前,且观察组LVEF均高于对照组,LVEDD均低于对照组,差异有统计学意义(P<0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。【结论】参松养心胶囊联合黛力新治疗冠心病PCI术后抑郁临床疗效较好,可明显改善患者临床症状、神经递质因子水平及心功能,且安全性良好。
【Objective】To explore the clinical efficacy of Shensong Yangxin Capsules combined with Deanxit in the treatment of patients with depression after percutaneous coronary intervention(PCI)for coronary heart disease(CHD).【Methods】A total of 102 patients with depression after PCI for CHD admitted to our hospital from June 2022 to December 2024 were selected.According to the random number table method,they were divided into the observation group(treated with Deanxit+Shensong Yangxin Capsules)and the control group(treated with Deanxit),with 51 cases in each group.After 3 months of treatment,the TCM syndrome scores,depression status,and clinical efficacy of the two groups were evaluated and compared.The neurotransmitter factors[brain-derived neurotrophic factor(BDNF),5-hydroxytryptamine(5-HT)],cardiac function indicators[left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF)],and the occurrence of adverse reactions were also compared between the two groups.【Results】The total clinical effective rate of the observation group was 94.12%(48/51),which was higher than 80.39%(41/51)of the control group,and the difference was statistically significant(P<0.05).At 1 month and 3 months after treatment,the serum levels of BDNF and 5-HT in both groups were higher than those before treatment,and the observation group was higher than the control group,with statistically significant differences(P<0.05).At 1 month and 3 months after treatment,the LVEF of both groups was higher than that before treatment,and the LVEDD was lower than that before treatment;the LVEF of the observation group was higher than that of the control group,and the LVEDD was lower than that of the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).【Conclusion】Shensong Yangxin Capsules combined with Deanxit has a good clinical efficacy in the treatment of depression after PCI for CHD.It can significantly improve the clinical symptoms of patients,enhance the levels of neurotransmitter factors and cardiac function,and has good safety.
作者
齐彦威
QI Yanwei(Department of Cardiology,the Liangyuan District Hospital of Traditional Chinese Medicine,Shangqiu Henan 476000)
出处
《医学临床研究》
2025年第8期1370-1373,1377,共5页
Journal of Clinical Research
关键词
冠心病
经皮冠状动脉介入治疗
抑郁
手术后并发症
Coronary Disease
Percutaneous Coronary Intervention
Depression
Postoperative Complications
